SCHEMBL5136072

SCHEMBL5136072

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OC)cc1)Cc1ccc(OCC)c(OCC)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
MAPT P10636 3/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
MAPK1 P28482 1/20 0.37
ALDH1A1 P00352 5/20 0.36
LMNA P02545 3/20 0.36
KDM4E B2RXH2 3/20 0.36
GAA P10253 3/20 0.36
TSHR P16473 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
PDE4B Q07343 1/20 0.36
POLB P06746 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
RXFP1 Q9HBX9 1/20 0.35
BCHE P06276 3/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135902 0.94 C5AR1 (0.42) C5AR1MEN1KMT2AMAPTALDH1A1
SCHEMBL647764 0.94 C5AR1 (0.47) C5AR1MEN1KMT2AMAPTMAPK1
SCHEMBL5135242 0.92 C5AR1 (0.45) C5AR1MEN1KMT2AMAPTL3MBTL1
SCHEMBL5136799 0.91 C5AR1 (0.43) C5AR1MAPTL3MBTL1ALDH1A1LMNA
SCHEMBL650402 0.90 C5AR1 (0.41) C5AR1MEN1KMT2AMAPTMAPK1
SCHEMBL651365 0.90 C5AR1 (0.46) C5AR1MAPTL3MBTL1ALDH1A1LMNA
SCHEMBL652044 0.90 C5AR1 (0.43) C5AR1MAPTALDH1A1LMNAKDM4E
SCHEMBL5137651 0.90 C5AR1 (0.42) C5AR1MAPTL3MBTL1ALDH1A1LMNA
SCHEMBL5072435 0.89 C5AR1 (0.46) C5AR1MEN1KMT2AMAPTMAPK1
SCHEMBL651447 0.89 C5AR1 (0.46) C5AR1MAPTMAPK1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed